Early outcomes with a fully retrievable SinoCrown transcatheter heart valve in patients with severe aortic stenosis

Abstract Background This study summarizes and analyzes data from patients suffering from symptomatic aortic stenosis who successfully underwent transcatheter aortic valve implantation (TAVI) using a novel, completely retrievable transcatheter heart valve. Methods We included patients who underwent a TAVI procedure with SinoCrown valves at our center between December 2021 and September 2022. We collected 1‐year follow‐up data on survival, complications, echocardiographic results, New York Heart Association functional class in heart failure, and patient‐reported health‐related quality of life outcomes. Results Eight successive patients (73.3 ± 4.3 years) were included in the study, with a median Society of Thoracic Surgery risk score of 4.26%. The procedure had a 100% success rate. Median postoperative discharge time was 7 days, with no 30‐day hospital readmissions. Postoperative aortic valve hemodynamics improved, indicated by decreased transvalvular flow velocity compared with preoperative values (1.9 ± 0.2 vs. 4.9 ± 0.2 m/s, p < 0.0001). The median and maximum follow‐up times were 8 and 12 months, respectively. During the follow‐up period, there were no serious complications such as death, stroke, valve embolization, or high‐grade atrioventricular block. Conclusions The results from eight initial TAVI cases performed with the SinoCrown valve demonstrated promising safety and efficacy.